Astellas suffers as US Prograf sales slump
This article was originally published in Scrip
Executive Summary
Astellas' group net sales fell by 7% to ¥461.7 billion ($5.74 billion) in the first half to 30 September, dragged down by plunging sales of its top global product, the immunosuppressant Prograf (tacrolimus).